Compare FLOC & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLOC | ACHV |
|---|---|---|
| Founded | 1996 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 855.7M | 726.5M |
| IPO Year | 2024 | 2018 |
| Metric | FLOC | ACHV |
|---|---|---|
| Price | $18.96 | $6.65 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 12 |
| Target Price | ★ $30.56 | $14.15 |
| AVG Volume (30 Days) | 511.8K | ★ 1.3M |
| Earning Date | 11-04-2026 | 11-05-2026 |
| Dividend Yield | ★ 1.91% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.52 | N/A |
| Revenue | ★ $759,719,000.00 | N/A |
| Revenue This Year | $25.40 | N/A |
| Revenue Next Year | $14.77 | N/A |
| P/E Ratio | $36.15 | ★ N/A |
| Revenue Growth | ★ 41.93 | N/A |
| 52 Week Low | $14.94 | $2.62 |
| 52 Week High | $28.26 | $8.64 |
| Indicator | FLOC | ACHV |
|---|---|---|
| Relative Strength Index (RSI) | 44.25 | 39.06 |
| Support Level | $18.66 | $5.84 |
| Resistance Level | $21.38 | $7.30 |
| Average True Range (ATR) | 0.64 | 0.38 |
| MACD | 0.08 | -0.09 |
| Stochastic Oscillator | 60.53 | 22.09 |
Flowco Holdings Inc is a provider of production optimization, artificial lift, emissions management, and monetization solutions for the oil and natural gas industry. Its technologies include high-pressure gas lift (HPGL), conventional gas lift, plunger lift, and vapor recovery unit (VRU) solutions. The company operates in two reportable segments: Production Solutions, which includes rental services, and Natural Gas Technologies, which include service, gas compression parts, and equipment sales. Production Solutions: relates to rentals, sales, and services related to high-pressure gas lift, conventional gas lift, and plunger lift; including other digital solutions and methane abatement technologies, and has maximum revenue. It generates maximum revenue from the United States.
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.